Author

Silong Xiang

Observed name: Xiang, Silong

Institution: CSPC Pharmaceutical Group

Observed institutions: Sichuan University, CSPC Pharmaceutical Group, 3D Medicines, Inc. (China)

OpenAlex ID: A5013662095

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

2021 · Jian Li, Yanhong Deng, et al. · Journal of Hematology & Oncology · 158

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

2022 · Toshio Shimizu, Takako Eguchi Nakajima, et al. · Investigational New Drugs · 51

Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer

2024 · Guiling Li, Xiaofan Li, et al. · Gynecologic Oncology · 11

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors

2024 · Jian Zhang, Yiqun Du, et al. · npj Precision Oncology · 11

Construction and characterization of an infectious replication competent clone of porcine endogenous retrovirus from Chinese miniature pigs

2013 · Silong Xiang, Yuyuan Ma, et al. · Virology Journal · 7

Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study.

2024 · Jin Zuo, Lingying Wu, et al. · Journal of Clinical Oncology · 6

Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.

2020 · Lin Shen, Jian Li, et al. · Journal of Clinical Oncology · 5

Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.

2026 · Zhi-Ming Shao, Peng Ji, et al. · Journal of Clinical Oncology · 4

Neoadjuvant Anbenitamab and HB1801 in ERBB2 -Positive Breast Cancer

2026 · Junjie Li, Tong Liu, et al. · JAMA Oncology · 2

Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer

2026 · Jiayu Wang, Huiping Li, et al. · New England Journal of Medicine · 1

Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors

2025 · Jian Fang, Ou Jiang, et al. · Drug Design Development and Therapy · 1

Enlonstobart in patients with PD-L1 positive recurrent/metastatic cervical cancer: Updated survival results of the phase II study.

2025 · Jing Zuo, Lingying Wu, et al. · Journal of Clinical Oncology

Works count: 14

Citation count: 257

H-index: 6

I10-index: 4